



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/528,295	10/25/2005	Klaus Muller	22596-536 NATL	6446
30623	7590	07/27/2010	EXAMINER	
MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.			ANDERSON, JAMES D	
ONE FINANCIAL CENTER			ART UNIT	PAPER NUMBER
BOSTON, MA 02111			1614	
MAIL DATE		DELIVERY MODE		
07/27/2010		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/528,295	<b>Applicant(s)</b> MULLER ET AL.
	<b>Examiner</b> JAMES D. ANDERSON	<b>Art Unit</b> 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 16 March 2005.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-42 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-42 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)  
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
 3) Information Disclosure Statement(s) (PTO/SB/08)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 4) Interview Summary (PTO-413)  
 Paper No(s)/Mail Date \_\_\_\_\_
- 5) Notice of Informal Patent Application  
 6) Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Election/Restrictions***

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-4, 18-19, 24-26, 31-32, and 37-38, drawn to compounds of Formula I, compositions comprising compounds of Formula I, and methods of treatment comprising administering compositions comprising a compound of Formula I. Please note additional Election of Species Requirements outlined below (Species Elections A and C)

Group II, claim(s) 5-17, 20-24, 27-30, 33-36, and 39-42, drawn to compounds of Formula II or Formula III, compositions comprising compounds of Formula II or III, and methods of treatment comprising administering a compound of Formula II or Formula III. Please note additional Election of Species Requirements outlined below (Species Elections B and C)

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the compounds of Formula I are distinct from the compounds of Formulas II and III and therefore there is no special technical feature linking the claims directed to compounds of Formula I and claims directed to compounds of Formula II or III.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

**Species Election A.** The multitude of compounds encompassed by the recited compound of Formula I. If Group I is elected, Applicants are required to elect a single disclosed species of Formula I (e.g., a compound of Formula I wherein X is S and R is phenyl);

**Specie Election B.** The multitude of compounds encompassed by the recited compounds of Formulas II and III. If Group II is elected, Applicants are required to elect a single disclosed specie of Formula II or Formula III (e.g., a compound of Formula II, wherein X is S and R is 3,4-dimethoxyphenyl). NOTE: If Applicants elect a compound of Formula III wherein R2 is H, claims 5-13 will be withdrawn as being drawn to non-elected species;

**Specie Election C.** The multitude of diseases and disorders encompassed by the recited "cell proliferative disorders". If Group I or Group II is elected, Applicants are required to elect a single disclosed cell proliferative disorder (e.g., wherein the cell proliferative disorder is cancer). NOTE: If Applicants elect the treatment of cancer, claims 37-42 will be withdrawn from consideration as being drawn to a non-elected specie. Likewise, if Applicants elect the treatment of psoriasis, claims 31-36 will be withdrawn as being drawn to a non-elected species.

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise require all the limitations of an allowed generic claim. Currently, the following claim(s) are generic: A) Claims 1-4, 18-19, 24-26, 31-32, and 37-38 are generic to compounds of Formula I; B) Claims 5-7; 14-15, 20-22, 24, 27-29, 33-35, and 39-41 are generic to compounds of Formula II and/or Formula III; and C) claims 24-30 are generic to "cell proliferative disorders".

The claims are deemed to correspond to the species listed above in the following manner:

Claims 1-4, 18-19, 24-26, 31-32, and 37-38 correspond to compounds of Formula I;  
Claims 5-17, 20-23, 27-30, 33-36, and 39-42 correspond to compounds of Formula II and/or  
Formula III;  
Claims 24-30 correspond to “cell proliferative disorders”;  
Claims 31-36 correspond to cancer or precancerous conditions; and  
Claims 37-42 correspond to psoriasis.

The following claim(s) are generic: A) Claims 1-4, 18-19, 24-26, 31-32, and 37-38 are generic to  
compounds of Formula I; B) Claims 5-7; 14-15, 20-22, 24, 27-29, 33-35, and 39-41 are generic  
to compounds of Formula II and/or Formula III; and C) claims 24-30 are generic to “cell  
proliferative disorders”.

#### REQUIREMENT FOR UNITY OF INVENTION

As provided in 37 CFR 1.475(a), a national stage application shall relate to one invention  
only or to a group of inventions so linked as to form a single general inventive concept  
("requirement of unity of invention"). Where a group of inventions is claimed in a national stage  
application, the requirement of unity of invention shall be fulfilled only when there is a technical  
relationship among those inventions involving one or more of the same or corresponding special  
technical features. The expression "special technical features" shall mean those technical features  
that define a contribution which each of the claimed inventions, considered as a whole, makes  
over the prior art.

The determination whether a group of inventions is so linked as to form a single general  
inventive concept shall be made without regard to whether the inventions are claimed in separate  
claims or as alternatives within a single claim. See 37 CFR 1.475(e).

WHEN CLAIMS ARE DIRECTED TO MULTIPLE CATEGORIES OF INVENTIONS

As provided in 37 CFR 1.475(b), a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) A process and an apparatus or means specifically designed for carrying out the said process; or
- (5) A product, a process specially adapted for the manufacture of the said product, and an apparatus or means specifically designed for carrying out the said process.

Otherwise, unity of invention might not be present. See 37 CFR 1.475(c).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement may be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of

election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention or species.

Should applicant traverse on the ground that the inventions have unity of invention (37 CFR 1.475(a)), applicant must provide reasons in support thereof. Applicant may submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. Where such evidence or admission is provided by applicant, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

***Joint Inventors***

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES D. ANDERSON whose telephone number is (571)272-9038. The examiner can normally be reached on MON-FRI 9:00 am - 5:00 pm EST.

Art Unit: 1614

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/James D Anderson/  
Primary Examiner, Art Unit 1614

July 22, 2010